[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1158
1. Chia A, Moreno G, Lim A, Shumack S: Actinic keratoses. Aust Fam Physician; 2007 Jul;36(7):539-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses.
  • Actinic keratoses (AK) commonly occur in the caucasian population living in environments of high levels of sun exposure, and are considered to be a marker for chronic sun damage.
  • This article reviews the epidemiology, pathogenesis, and current debate on AK as precancerous lesions.
  • The various treatment options for AK, including combination therapy, are also discussed.

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17619671.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antimetabolites; 144O8QL0L1 / Diclofenac; U3P01618RT / Fluorouracil
  • [Number-of-references] 34
  •  go-up   go-down


2. Dixon A: Treating actinic keratoses with imiquimod. Aust Fam Physician; 2007 May;36(5):341-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating actinic keratoses with imiquimod.
  • Mr KC, 61 years of age, has extensive actinic damage including squamous cell carcinomas (SCCs) and actinic keratoses (AKs) on his face and forehead.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Facial Dermatoses / drug therapy. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492069.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


3. Krathen M, Treat J, James WD: Capecitabine induced inflammation of actinic keratoses. Dermatol Online J; 2007;13(4):13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine induced inflammation of actinic keratoses.
  • Patients undergoing capecitabine therapy may experience inflammation and irritation of existing actinic keratoses.
  • [MeSH-minor] Aged. Capecitabine. Female. Humans. Keratosis / etiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18319010.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Atkins D, Bang RH, Sternberg MR, Chen SC: Reliable methods to evaluate the burden of actinic keratoses. J Invest Dermatol; 2006 Mar;126(3):591-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reliable methods to evaluate the burden of actinic keratoses.
  • Dermatologists treat actinic keratoses to prevent non-melanoma skin cancer.
  • Evaluation of actinic keratosis therapy depends on reliable measures of the lesions.
  • Our study demonstrates that both methods are viable ways to evaluate actinic keratoses, even when the investigators differ at different time points, a practical matter in clinical trials.
  • Our study provides a promising option to evaluate emerging new actinic keratoses therapies.
  • [MeSH-major] Keratosis / diagnosis. Precancerous Conditions / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397520.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23AR02185-01A1; United States / NIAMS NIH HHS / AR / P30AR42687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. McIntyre WJ, Downs MR, Bedwell SA: Treatment options for actinic keratoses. Am Fam Physician; 2007 Sep 1;76(5):667-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for actinic keratoses.
  • Actinic keratoses are rough, scaly lesions that commonly occur on sun-exposed areas of the skin.
  • Actinic keratoses are thought to be carcinomas in situ, which can progress to squamous cell carcinomas.
  • Fluorouracil has been the traditional topical treatment for actinic keratoses, although imiquimod 5% cream and diclofenac 3% gel are effective alternative therapies.
  • [MeSH-major] Keratosis / therapy

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am Fam Physician. 2008 Apr 15;77(8):1078-9 [18481555.001]
  • (PMID = 17894135.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 39
  •  go-up   go-down


6. Foote JA, Ranger-Moore JR, Einspahr JG, Saboda K, Kenyon J, Warneke J, Miller RC, Goldman R, Xu MJ, Roe DJ, Alberts DS: Chemoprevention of human actinic keratoses by topical DL-alpha-tocopherol. Cancer Prev Res (Phila); 2009 Apr;2(4):394-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of human actinic keratoses by topical DL-alpha-tocopherol.
  • Contralateral arms of healthy human volunteers with actinic keratoses (AK) were randomly assigned to receive either 12.5% DL-alpha-tocopherol or placebo in a crème base for 6 months.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VITAMIN E .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 1973 Dec 16;13(12):1635-47 [4591188.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):149-55 [11801552.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Biochimie. 1988 Dec;70(12):1709-13 [3150673.001]
  • [Cites] Nutr Cancer. 1991;15(2):97-106 [2038569.001]
  • [Cites] J Am Acad Dermatol. 1992 May;26(5 Pt 1):744-8 [1583174.001]
  • [Cites] Am J Pathol. 1992 Jul;141(1):139-42 [1352943.001]
  • [Cites] J Cutan Pathol. 1992 Dec;19(6):458-68 [1362576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):139-44 [8467248.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Cancer Lett. 1994 Sep 30;85(1):23-9 [7923098.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):343-8 [9162299.001]
  • [Cites] Nutr Cancer. 1996;26(2):183-91 [8875555.001]
  • [Cites] Nutr Cancer. 1996;26(2):193-201 [8875556.001]
  • [Cites] Free Radic Biol Med. 1997;22(3):573-8 [8981051.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):203-5 [9103292.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2630-7 [9205069.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1195-202 [9214603.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):583-7 [9264270.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1263-70 [9382565.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):949-56 [9367069.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1654-9 [9563478.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):681-6 [9591810.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] J Invest Dermatol. 2008 Dec;128(12):2905-8 [18615112.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Neoplasia. 1999 Nov;1(5):468-75 [10933063.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001;14 Suppl 1:87-91 [11509912.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1212-7 [11710935.001]
  • [Cites] Biochem Med. 1979 Apr;21(2):168-81 [465013.001]
  • (PMID = 19336724.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / CA-23074; United States / NCI NIH HHS / CA / CA-27502
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biogenic Polyamines; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; H4N855PNZ1 / alpha-Tocopherol
  • [Other-IDs] NLM/ NIHMS616770; NLM/ PMC4154592
  •  go-up   go-down


7. Shoimer I, Rosen N, Muhn C: Current management of actinic keratoses. Skin Therapy Lett; 2010 May;15(5):5-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of actinic keratoses.
  • An actinic keratosis (AK) is a pre-malignant cutaneous lesion that frequently manifests in sun-exposed areas of the skin as a small, rough, scaly erythematous papule.
  • [MeSH-major] Carcinoma, Squamous Cell / prevention & control. Keratosis, Actinic / therapy. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505896.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Hermanns JF, Piérard GE, Quatresooz P: Erlotinib-responsive actinic keratoses. Oncol Rep; 2007 Sep;18(3):581-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erlotinib-responsive actinic keratoses.
  • Erlotinib is an inhibitor of the tyrosine-kinase domain of the epidermal growth factor receptor-1 (EGFR).
  • We described the incidental effect of erlotinib on actinic keratoses which became markedly inflamed and showed partial regression.
  • [MeSH-major] Keratosis / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / prevention & control. Carcinoma, Squamous Cell / radionuclide imaging. Erlotinib Hydrochloride. Humans. Inflammation. Male. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Skin Neoplasms / etiology. Skin Neoplasms / prevention & control. Skin Neoplasms / radionuclide imaging. Sunlight / adverse effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671704.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


9. Fenske NA, Spencer J, Adam F: Actinic keratoses: past, present and future. J Drugs Dermatol; 2010 May;9(5 Suppl ODAC Conf Pt 1):s45-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: past, present and future.
  • Actinic keratoses (AKs) are cutaneous neoplasms composed of proliferations of cytologically aberrant, epidermal keratinocytes caused by prolonged exposure to ultraviolet radiation.
  • Combining the evidence that AKs are the second most common reason for visits to the dermatologist and it is generally believed that they should be treated, it is no surprise that the direct cost of the management of actinic keratoses in the United States (U.S.) is exceedingly high.
  • The future of AK treatment involves both the continued investigation of current novel therapies, as well as the development of new treatment modalities.
  • [MeSH-major] Keratosis, Actinic / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518359.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunosuppressive Agents; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 33
  •  go-up   go-down


10. Kalisiak MS, Rao J: Photodynamic therapy for actinic keratoses. Dermatol Clin; 2007 Jan;25(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for actinic keratoses.
  • Actinic keratoses (AKs) are one of the most common conditions that are treated by dermatologists and they have the potential to progress to squamous cell carcinoma if left untreated.
  • This article focuses on practical aspects of PDT in the treatment of AKs, outcomes of relevant clinical trials, and special applications of PDT in transplant recipients and other who are predisposed to AK formation.
  • [MeSH-major] Keratosis / drug therapy. Photochemotherapy. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126738.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 39
  •  go-up   go-down


11. Morton CA: Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin; 2007 Jan;25(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolevulinate: actinic keratoses and Bowen's disease.
  • Topical photodynamic therapy (PDT) using the methyl ester of 5-aminolaevulinic acid (MAL) is an effective therapy for actinic keratoses and Bowen's disease.
  • Thin and moderate thickness facial actinic keratoses respond best, with clearance rates equivalent or superior (depending on protocol) to current therapy, and with notably superior cosmetic outcome.
  • The response rate of Bowen's disease to MAL-PDT is also at least equivalent to cryotherapy and 5-fluorouracil, again with superior cosmesis.
  • Patients with large or multiple lesions of Bowen's disease or those in whom standard therapy, including surgery, is relatively contraindicated may particularly benefit from PDT.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Bowen's Disease / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126745.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 27
  •  go-up   go-down


12. de Berker D, McGregor JM, Hughes BR, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee: Guidelines for the management of actinic keratoses. Br J Dermatol; 2007 Feb;156(2):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the management of actinic keratoses.
  • Following this meeting one of the authors (J.M.M.) was invited to draw up guidelines for the management of actinic keratoses by the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee.
  • Relevant evidence was sought using the search terms 'solar keratosis' and 'actinic keratosis' in Medline from 1966 onwards.
  • [MeSH-major] Keratosis / therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Dermatol. 2008 Apr;158(4):873
  • (PMID = 17223860.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents
  •  go-up   go-down


13. Bagatin E, Teixeira SP, Hassun KM, Pereira T, Michalany NS, Talarico S: 5-Fluorouracil superficial peel for multiple actinic keratoses. Int J Dermatol; 2009 Aug;48(8):902-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil superficial peel for multiple actinic keratoses.
  • BACKGROUND: Chronically photodamaged skin usually presents with multiple, widespread, actinic keratoses (AKs), and treatment of the entire affected area is recommended.
  • RESULTS: All patients achieved a satisfactory result, including the complete regression, or at least 80% clearing, of AK lesions and an overall improvement of photodamaged skin.
  • [MeSH-major] Chemexfoliation / methods. Fluorouracil / administration & dosage. Keratolytic Agents / administration & dosage. Keratosis, Actinic / drug therapy

  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. HYDROXYACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19659874.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Glycolates; 0 / Jessner's solution; 0 / Keratolytic Agents; 0 / Resorcinols; 0 / Salicylates; 33X04XA5AT / Lactic Acid; 3K9958V90M / Ethanol; 79-14-1 / glycolic acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Helm K, Findeis-Hosey J: Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A. J Cutan Pathol; 2008 Oct;35(10):931-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A.
  • Distinguishing lentigo maligna from solar lentigo, and pigmented actinic keratosis can sometimes be problematic.
  • We compared Melan-A immunohistochemical staining in pigmented actinic keratosis , non-pigmented actinic keratoses , melanoma in situ of lentigo maligna type and solar lentigines.
  • We found a statistically significant increase of Melan-A staining in melanoma in situ, but no statistical difference in the number of junctional Melan-A positively staining cells, in solar lentigines, pigmented actinic keratoses, and non-pigmented actinic keratoses, respectively.
  • In the non non-melanoma samples, the Melan-A A-positive cells located at the dermal-epidermal junction were interspersed and not observed in clusters.
  • Increased staining with Melan-A, in an actinic keratosis, or solar lentigo should raise the possibility of a contiguous melanoma in situ.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Hutchinson's Melanotic Freckle / diagnosis. Keratosis, Actinic / diagnosis. Lentigo / diagnosis. Melanoma / diagnosis. Neoplasm Proteins / biosynthesis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2010 Aug;37(8):917-8 [19804418.001]
  • (PMID = 18494818.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


15. Jirakulaporn T, Mathew J, Lindgren BR, Dudek AZ: Efficacy of capecitabine in secondary prevention of skin cancer in solid organ-transplanted recipients (OTR). J Clin Oncol; 2009 May 20;27(15_suppl):1519
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical 5% 5-FU has been used to successfully treat squamous cell carcinoma (SCC) in situ and actinic keratosis (AK).
  • Cumulative incidence rates of SCC, BCC, and AK before and after treatment were scored and statistically compared for each patient with a non-parametric Wilcoxon signed-rank test.
  • Mean incidence rates of SCC, BCC, and AK before treatment were 0.45, 0.05, and 4.99 lesions per month, respectively.
  • Mean incidence rates of SCC, BCC, and AK after treatment were 0.22, 0.04, and 2.80 lesions per month, respectively.
  • The differences in incidence rates of SCC, BCC, and AK before and after treatment were 0.24, 0.02, and 2.08 lesions per month with p value of 0.048, 0.844, and 0.151, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964327.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Weinberg JM: Topical therapy for actinic keratoses: current and evolving therapies. Rev Recent Clin Trials; 2006 Jan;1(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical therapy for actinic keratoses: current and evolving therapies.
  • Actinic keratoses (AKs) are evolving malignant cutaneous neoplasms.
  • They are also known as solar keratosis, squamous cell carcinoma in situ-solar keratotic type, or keratinocytic intraepidermal neoplasia.
  • Actinic keratoses can be treated by two general methods: by physical/destructive methods and with topical therapies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Keratosis / drug therapy. Neoplasms, Squamous Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. COLCHICINE .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393780.001).
  • [ISSN] 1574-8871
  • [Journal-full-title] Reviews on recent clinical trials
  • [ISO-abbreviation] Rev Recent Clin Trials
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Retinoids; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; SML2Y3J35T / Colchicine; U3P01618RT / Fluorouracil
  • [Number-of-references] 66
  •  go-up   go-down


17. Petit A: [Actinic keratoses are still actinic keratoses]. Ann Dermatol Venereol; 2008 Feb;135(2):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Actinic keratoses are still actinic keratoses].
  • [MeSH-major] Keratosis / diagnosis. Photosensitivity Disorders / diagnosis
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Disease Progression. Humans. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Terminology as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342088.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Editorial
  • [Publication-country] France
  •  go-up   go-down


18. Spencer JM, Hazan C, Hsiung SH, Robins P: Therapeutic decision making in the therapy of actinic keratoses. J Drugs Dermatol; 2005 May-Jun;4(3):296-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic decision making in the therapy of actinic keratoses.
  • Actinic keratoses (AKs) represent the second most common reason to visit a dermatologist in the United States and their therapy has become a major portion of most dermatologists' practice.
  • An ever-increasing array of therapeutic options exist for the therapy of actinic keratoses, offering physicians and patients a greater number of choices than ever before.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Keratosis / drug therapy. Photochemotherapy / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898284.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic
  • [Number-of-references] 27
  •  go-up   go-down


19. Ilyas EN, Grana G, Green JJ: Inflammatory actinic keratoses secondary to systemic chemotherapy. Cutis; 2005 Mar;75(3):167-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory actinic keratoses secondary to systemic chemotherapy.
  • Traditionally, systemic 5-fluorouracil has been associated with a reaction that produces inflammation of preexisting and subclinical actinic keratoses (AKs).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Doxorubicin / adverse effects. Keratosis / etiology. Ultraviolet Rays / adverse effects

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839360.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


20. Dianzani C, Pierangeli A, Chiricozzi A, Avola A, Degener AM: Cutaneous human papillomaviruses as recurrence factor in actinic keratoses. Int J Immunopathol Pharmacol; 2008 Jan-Mar;21(1):145-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous human papillomaviruses as recurrence factor in actinic keratoses.
  • Actinic keratoses (AK) are common, premalignant lesions cause mainly by UV DNA damage.
  • The aim of this work is to identify the presence of HPV DNA in biopsies from Actinic Keratoses (AK) and from normal skin samples collected from dermatological healthy subjects in Italy, in order to evaluate the severity and the clinical evolution of the HPV positive lesions.
  • The DNA test revealed 37% HPV positivity in AK patients versus 0% in the control group; many different genotypes and variants were identified by direct sequencing of PCR product.
  • The HPV positive AK were usually clinically indistinguishable from the HPV negative.
  • All AK lesions were removed by laser treatment, but AK lesions recurred in all HPV positive patients after a period of 45-60 days whereas the same disappeared in the HPV negative ones.
  • These data permit to hypothesize that the presence of HPV DNA could be an aggravating factor for AK lesion severity and recurrence.
  • [MeSH-major] Keratosis / virology. Papillomaviridae / isolation & purification. Skin / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336740.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


21. Wheeland RG: The pitfalls of treating all actinic keratoses as squamous cell carcinomas. Semin Cutan Med Surg; 2005 Sep;24(3):152-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pitfalls of treating all actinic keratoses as squamous cell carcinomas.
  • The greatest difficulties in managing a patient with numerous actinic keratoses is deciding the order in which to treat the specific lesions and what modality to use.
  • If the patient's health insurance company limits coverage for the treatment of a specific number AK's per visit, it may be most prudent and logical to begin treatment of the largest or most rapidly growing AK's first and continue treatment of remaining lesions at subsequent visits until all lesions have been eradicated.
  • [MeSH-major] Keratosis / pathology. Keratosis / therapy. Photosensitivity Disorders / pathology. Photosensitivity Disorders / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202952.001).
  • [ISSN] 1085-5629
  • [Journal-full-title] Seminars in cutaneous medicine and surgery
  • [ISO-abbreviation] Semin Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


22. Braathen LR, Paredes BE, Saksela O, Fritsch C, Gardlo K, Morken T, Frølich KW, Warloe T, Solér AM, Ros AM: Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses. J Eur Acad Dermatol Venereol; 2009 May;23(5):550-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short incubation with methyl aminolevulinate for photodynamic therapy of actinic keratoses.
  • BACKGROUND: Photodynamic therapy (PDT) using methyl aminolevulinate (MAL) is an effective first-line treatment for actinic keratoses.
  • OBJECTIVE: This study aims to evaluate the effect of incubation time (1 vs. 3 h), MAL concentration (160 mg/g vs. 80 mg/g) and lesion preparation in the setting of MAL-PDT for treatment of actinic keratosis (AK).
  • SUBJECTS: One hundred and twelve patients with 384 previously untreated AK.
  • RESULTS: For lesions on the face/scalp, lesion complete response rates were 78% for thin AK and 74% for moderately thick AK lesions after 1 h vs. 96% and 87% after 3 h incubation with MAL 160 mg/g.
  • CONCLUSION: MAL-PDT using a 1-h incubation may be sufficient for successful treatment of selected AK lesions.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415804.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


23. Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E, Astner S: Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol; 2007 May;156 Suppl 3:13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: non-invasive diagnosis for field cancerisation.
  • BACKGROUND: Actinic keratoses (AKs) are among the most common cutaneous malignancies and have previously been classified as in situ squamous cell carcinoma (SCC) with reported progression rates of up to 20% over 10 years.
  • In vivo reflectance confocal microscopy (RCM) has been used for evaluation of the morphological features of non-melanoma skin cancer (NMSC) and RCM evaluation parameters for the diagnosis of AKs have been reported.
  • PATIENTS/METHODS: Forty four Caucasians (SPT I-III) with a minimum of one actinic keratosis (AK) lesion were included in this study.
  • Following blinded evaluation by two independent investigators, 97.7% of all skin samples were identified as AK using RCM.
  • 2.3% were incorrectly identified as normal skin by RCM, while routine histology showed features consistent with AK.
  • CONCLUSIONS: Reflectance confocal microscopy may be a feasible alternative in the diagnosis of AK and may aid in the differentiation against normal skin, as well as in the detection of subclinical disease.
  • [MeSH-major] Keratosis / pathology. Precancerous Conditions / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Disease Progression. Humans. Microscopy, Confocal / methods. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488401.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Scheinfeld NS: Actinic keratoses. Skinmed; 2007 Jul-Aug;6(4):188-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses.
  • [MeSH-major] Keratosis. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Lentigo / diagnosis. Male. Precancerous Conditions. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618171.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Stockfleth E: Actinic keratoses. Cancer Treat Res; 2009;146:227-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses.
  • [MeSH-major] Keratosis, Actinic / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Aged. Aminoquinolines / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Cryotherapy / methods. Dermatology / methods. Fluorouracil / therapeutic use. Humans. Lasers. Medical Oncology / methods. Models, Biological. Organ Transplantation / adverse effects. Photochemotherapy / methods. Retinoids / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415207.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Retinoids; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 72
  •  go-up   go-down


26. Horn M, Gerger A, Ahlgrimm-Siess V, Weger W, Koller S, Kerl H, Samonigg H, Smolle J, Hofmann-Wellenhof R: Discrimination of actinic keratoses from normal skin with reflectance mode confocal microscopy. Dermatol Surg; 2008 May;34(5):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrimination of actinic keratoses from normal skin with reflectance mode confocal microscopy.
  • BACKGROUND: Recently, a wide range of new noninvasive therapies has been introduced for the treatment of actinic keratoses.
  • As these treatment options do not provide tissue for histopathologic examination, in vivo confocal laser scanning microscopy may become an important method for obtaining a reliable diagnosis.
  • OBJECTIVE: The objective was to validate the diagnostic confocal examination of actinic keratoses.
  • METHODS: Thirty actinic keratoses and skin fields from the contralateral sides of the patients were consecutively sampled and examined using a confocal microscope.
  • RESULTS: Distinct diagnostic morphologic features could be visualized.
  • Classification and regression tree analysis yielded a one-step algorithm based on only one criterion (irregular keratinocyte cell borders), facilitating a correct classification in 86.67% of actinic keratoses and 85% of normal skin.
  • LIMITATIONS: Hyperkeratotic actinic keratoses were excluded from the study set.
  • CONCLUSIONS: This study provides a set of morphologic confocal microscopy criteria showing promise as a noninvasive monitoring tool in the treatment of actinic keratoses.
  • [MeSH-major] Keratosis / pathology. Microscopy, Confocal / methods. Skin / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Keratinocytes / pathology. Male. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429925.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


27. Kozyreva ON, Konnikov N: The incidence of non-melanoma skin cancer after a single field treatment with aminolevulinic acid and blue light photodynamic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e14646
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Study population included immunocompetent pts with history of NMSC, multiple actinic keratosis (AKs), and moderate to severe dermatoheliosis (DH).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964235.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Zouboulis CC, Röhrs H: [Cryosurgical treatment of actinic keratoses and evidence-based review]. Hautarzt; 2005 Apr;56(4):353-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cryosurgical treatment of actinic keratoses and evidence-based review].
  • BACKGROUND: Actinic keratoses are focal epithelial carcinomas in situ, which are considered precursors of squamous cell carcinoma and must therefore be treated.
  • In the USA, cryosurgery is the most frequent surgical procedure for the treatment of actinic keratoses and considered the treatment of choice.
  • METHODS: Our own results of cryosurgical treatment of actinic keratoses were evaluated.
  • Original publications and reviews on the treatment of actinic keratoses with cryosurgery were retrieved from MEDLINE and classified according to their evidence level.
  • CONCLUSIONS: Cryosurgery is beneficial in the treatment of actinic keratoses.
  • [MeSH-major] Cryosurgery / methods. Cryosurgery / statistics & numerical data. Keratosis / epidemiology. Keratosis / surgery. Photosensitivity Disorders / epidemiology. Photosensitivity Disorders / surgery. Risk Assessment / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15580450.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down


29. Hauschild A, Kähler KC, Egberts F: [Modern treatment modalities in actinic keratoses of the skin]. Dtsch Med Wochenschr; 2006 Mar 3;131(9):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern treatment modalities in actinic keratoses of the skin].
  • It has been estimated that approximately 4 million Germans are suffering from actinic keratoses, which are considered as a carcinoma in situ today.
  • Typically, actinic keratoses appear in sun-exposed skin areas, conventionally they have been treated by curettage and cryotherapy.
  • The rate of complete clearance from actinic keratoses varies between 50 and 90 % in clinical trials.
  • [MeSH-major] Keratosis / therapy. Photosensitivity Disorders / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493570.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Retinoids; 0 / Sunscreening Agents
  • [Number-of-references] 33
  •  go-up   go-down


30. Naldi L, Chatenoud L, Piccitto R, Colombo P, Placchesi EB, La Vecchia C, Prevalence of Actinic Keratoses Italian Study (PraKtis) Group: Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. Arch Dermatol; 2006 Jun;142(6):722-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004.
  • OBJECTIVE: The Prevalence of Actinic Keratoses Italian Study (PraKtis) was designed to estimate the point prevalence of actinic keratoses (AKs) and associated factors in a representative sample of the Italian adult population.
  • [MeSH-major] Keratosis / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785374.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Alexiades-Armenakas M: Aminolevulinic acid photodynamic therapy for actinic keratoses/actinic cheilitis/acne: vascular lasers. Dermatol Clin; 2007 Jan;25(1):25-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminolevulinic acid photodynamic therapy for actinic keratoses/actinic cheilitis/acne: vascular lasers.
  • In particular, LP PDL PDT has been shown to be safe and effective in the treatment of actinic keratoses, actinic cheilitis, photodamage, and acne vulgaris with minimal discomfort, rapid treatment and recovery, and excellent posttreatment cosmesis.
  • [MeSH-major] Acne Vulgaris / drug therapy. Aminolevulinic Acid / therapeutic use. Cheilitis / drug therapy. Keratosis / drug therapy. Low-Level Light Therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Ultraviolet Rays / adverse effects

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • MedlinePlus Health Information. consumer health - Acne.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126739.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 72
  •  go-up   go-down


32. Ibrahim SF, Brown MD: Actinic keratoses: a comprehensive update. J Clin Aesthet Dermatol; 2009 Jul;2(7):43-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: a comprehensive update.
  • Actinic keratoses are common intra-epidermal neoplasms that lie on a continuum with squamous cell carcinoma.
  • Tightly linked to ultraviolet irradiation, they occur in areas of chronic sun exposure, and early treatment of these lesions may prevent their progression to invasive disease.
  • Several previously experimental options, such as imiquimod and photodynamic therapy, have become incorporated as first-line options for the treatment of actinic keratoses, while combination treatment strategies have been gaining in popularity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1029-31 [2064402.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1031-3 [2064403.001]
  • [Cites] Br J Dermatol. 1986 Dec;115(6):649-55 [3801305.001]
  • [Cites] Dermatol Surg. 1996 Jan;22(1):17-21 [8556252.001]
  • [Cites] Dermatol Surg. 1997 Mar;23(3):191-6 [9145962.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):23-4 [10607353.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):22-9 [12353677.001]
  • [Cites] Arch Dermatol. 2003 Apr;139(4):451-5 [12707092.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • [Cites] Arch Dermatol. 2004 Jul;140(7):813-6 [15262691.001]
  • [Cites] Int J Dermatol. 2004 Sep;43(9):687-92 [15357755.001]
  • [Cites] J Drugs Dermatol. 2005 May-Jun;4(3):296-301 [15898284.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):659-64 [15996416.001]
  • [Cites] Arch Dermatol Res. 2005 Nov;297(5):185-9 [16235081.001]
  • [Cites] Dermatol Surg. 2006 Feb;32(2):261-7 [16442048.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1251-5 [16557235.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):9-22 [16792746.001]
  • [Cites] Lasers Surg Med. 2006 Sep;38(8):731-9 [16912977.001]
  • [Cites] Dermatol Surg. 2006 Aug;32(8):1045-9 [16918567.001]
  • [Cites] Dermatol Surg. 2006 Oct;32(10):1261-5 [17034376.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):1029-36 [17034536.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jun;65(6):1135-9 [17517297.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:34-40 [18067630.001]
  • [Cites] J Cutan Med Surg. 2008 May-Jun;12(3):97-101 [18544290.001]
  • [Cites] J Drugs Dermatol. 2008 Jul;7(7):669-73 [18664159.001]
  • [Cites] J Am Acad Dermatol. 2009 Jan;60(1):59-62 [18937999.001]
  • (PMID = 20729970.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2924136
  •  go-up   go-down


33. Ulrich M, Stockfleth E: Field treatment of actinic keratoses - focus on COX-2-inhibitors. Actas Dermosifiliogr; 2009 Dec;100 Suppl 2:55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Field treatment of actinic keratoses - focus on COX-2-inhibitors.
  • Actinic keratoses (AK) represent the most common carcinoma in situ of the skin and show continuously increasing incidences worldwide.
  • Clinically, AK occur as multiple lesions in sun-exposed areas, which has been referred to as field cancerization.
  • Novel treatment modalities for actinic field cancerization include 3 % diclofenac in 2.5 % hyaluronic acid (HA).
  • Herein, we give an overview about actinic keratosis focusing on treatment with the COX-2 inhibitor diclofenac 3 % gel and summarize current concepts of its antineoplastic mode of action.
  • [MeSH-major] Cyclooxygenase 2 Inhibitors / therapeutic use. Keratosis, Actinic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096163.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors
  •  go-up   go-down


34. Iraji F, Siadat AH, Asilian A, Enshaieh S, Shahmoradi Z: The safety of diclofenac for the management and treatment of actinic keratoses. Expert Opin Drug Saf; 2008 Mar;7(2):167-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The safety of diclofenac for the management and treatment of actinic keratoses.
  • BACKGROUND: Actinic keratoses (AKs), defined as carcinoma in situ of squamous carcinoma, is usually induced by excessive sun exposure.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Carcinoma in Situ / drug therapy. Diclofenac / adverse effects. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324879.001).
  • [ISSN] 1744-764X
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  • [Number-of-references] 16
  •  go-up   go-down


35. Ortiz-Policarpio B, Lui H: Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers. Skin Therapy Lett; 2009 Jul-Aug;14(6):1-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers.
  • Methyl aminolevulinate-hydrochloride cream (Metvix [in Canada] and Metvixia [in the US], Galderma) in combination with photodynamic therapy (PDT) provides an effective treatment option for actinic keratoses (AKs), superficial basal cell carcinoma (sBCC), and Bowen's disease (BD).
  • Complete responses (CRs) in AK range from 69% to 93% at 3 months.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Combined Modality Therapy. Humans. Treatment Outcome. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609473.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 20
  •  go-up   go-down


36. Ulrich M, Krueger-Corcoran D, Roewert-Huber J, Sterry W, Stockfleth E, Astner S: Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology; 2010;220(1):15-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses.
  • BACKGROUND: Actinic keratoses (AK) represent cutaneous carcinoma in situ and have previously been evaluated by reflectance confocal microscopy (RCM).
  • Treatment of AK with imiquimod (IMIQ) 5% cream has been shown to 'highlight' subclinical lesions.
  • OBJECTIVE: The aim of this study was to test the applicability of RCM for noninvasive monitoring of actinic field cancerization and detection of subclinical AK.
  • SUBJECTS AND METHODS: AK and surrounding skin sites with no apparent AK of 11 volunteers were selected for imaging and subsequently classified as 'clinical' and 'subclinical' AK.
  • RESULTS: RCM was able to detect morphologic features of AK in both clinical and subclinical AK; features were more pronounced in clinical lesions.
  • CONCLUSION: Our findings indicate that RCM allows noninvasive monitoring of treatment response in vivo and permits early detection of subclinical AK, thus substantiating the incentive for therapy.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Drug Monitoring / methods. Keratosis, Actinic / drug therapy. Microscopy, Confocal / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19907131.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


37. Tan JK, Thomas DR, Poulin Y, Maddin F, Tang J: Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg; 2007 Nov-Dec;11(6):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses.
  • BACKGROUND: Cryotherapy is the standard of care for clinically apparent (target) actinic keratoses (AKs).
  • At 12 weeks, target AK clearance was similar for imiquimod and vehicle (79% vs 76%), but fewer total AKs were noted for imiquimod (78 vs 116).
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Facial Dermatoses / drug therapy. Keratosis / drug therapy. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042331.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Ointments; P1QW714R7M / imiquimod
  •  go-up   go-down


38. Gilbert DJ: Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol; 2005 Mar-Apr;4(2):161-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy.
  • Actinic keratoses (AKs) are traditionally treated with cryotherapy, curettage, and 5-fluorouracil (5-FU, Efudex, ICN Pharmaceuticals, Inc.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Facial Dermatoses / drug therapy. Fluorouracil / administration & dosage. Keratosis / drug therapy. Photochemotherapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776772.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Somani N, Rivers JK: Imiquimod 5% cream for the treatment of actinic keratoses. Skin Therapy Lett; 2005 Mar;10(2):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream for the treatment of actinic keratoses.
  • Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC).
  • Five clinical studies to date have demonstrated its safety and efficacy in the treatment of actinic keratoses.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Keratosis / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986078.001).
  • [ISSN] 1201-5989
  • [Journal-full-title] Skin therapy letter
  • [ISO-abbreviation] Skin Therapy Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


40. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J, Majewski S, Pfister H, Wieland U: Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol; 2005 Jul;125(1):93-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers.
  • In this study viral DNA loads of six frequent HPV types were determined by quantitative, type-specific real-time-PCR (Q-PCR) in actinic keratoses (AK, n=26), NMSC (n=31), perilesional tissue (n=22), and metastases of squamous cell carcinomas (SCC) (n=8) which were previously shown to be positive for HPV5, 8, 15, 20, 24, or 36.
  • HPV-DNA loads in AK, (partially microdissected) NMSC, and perilesional skin ranged between one HPV-DNA copy per 0.02 and 14,200 cell equivalents (median: 1 HPV-DNA copy per 344 cell equivalents; n=48).
  • But, viral loads found in AK were significantly higher than in SCC (p=0.035).
  • [MeSH-major] Carcinoma, Squamous Cell / virology. DNA Probes, HPV. DNA, Viral / analysis. Keratosis / virology. Papillomaviridae / isolation & purification. Skin Neoplasms / virology. Viral Load

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2005 Jul;125(1):xii-xiii [15982294.001]
  • (PMID = 15982308.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV; 0 / DNA, Viral
  •  go-up   go-down


41. Resnick L, Rabinovitz H, Binninger D, Marchetti M, Weissbach H: Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. J Drugs Dermatol; 2009 Jan;8(1):29-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses.
  • BACKGROUND: Actinic keratoses (AKs) are a precancerous condition of the skin that have the potential to become squamous cell cancer (SCC).
  • METHODS: Cell culture studies were performed using a skin SCC cell line and normal human epidermal keratinocytes.
  • A clinical trial using the combination of sulindac and hydrogen peroxide therapy in 5 patients with AKs revealed that 60% of the treated AKs responded and 50% showed no residual AK on histopathology specimens after skin biopsy.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / therapeutic use. Hydrogen Peroxide / therapeutic use. Keratosis, Actinic / drug therapy. Oxidants / therapeutic use. Sulindac / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180893.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R15 CA122001-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Gels; 0 / Oxidants; 0 / Reactive Oxygen Species; 184SNS8VUH / Sulindac; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


42. DeBoyes T, Kouba D, Ozog D, Fincher E, Moy L, Iwata K, Moy R: Reduced number of actinic keratoses with topical application of DNA repair enzyme creams. J Drugs Dermatol; 2010 Dec;9(12):1519-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced number of actinic keratoses with topical application of DNA repair enzyme creams.
  • BACKGROUND: Actinic keratosis is regarded as a carcinoma in situ by some dermatologists and its incidence continues to rise.
  • DNA repair enzymes have been shown to reverse sun-damage, resulting in reduced rates of actinic keratoses and non-melanoma skin cancers in specific patient populations.
  • METHODS: Seventeen patients were evaluated for differences in actinic keratoses following topical application of T4N5 liposome lotion over 48 weeks.
  • RESULTS: Compared to baseline, a statistically significant reduction in the number of actinic keratoses was seen following the treatment period.
  • DISCUSSION: This study suggests that DNA repair enzyme creams effectively reduce the number of actinic keratoses in normal individuals with moderate-to-severe photodamaged skin.
  • [MeSH-major] DNA Repair Enzymes / therapeutic use. Deoxyribonuclease (Pyrimidine Dimer) / therapeutic use. Keratosis, Actinic / drug therapy. Viral Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21120260.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / Viral Proteins; 0 / endonuclease V, phage T4; EC 3.1.25.1 / Deoxyribonuclease (Pyrimidine Dimer); EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


43. Russo GG: Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments. Clin Dermatol; 2005 Nov-Dec;23(6):581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments.
  • This contribution will discuss the treatment of actinic keratoses, basal cell carcinomas, and squamous cell carcinoma using methods that are not routinely established but have been used for a long period.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Keratosis / drug therapy. Photosensitivity Disorders / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. COLCHICINE .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325066.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid; SML2Y3J35T / Colchicine
  • [Number-of-references] 53
  •  go-up   go-down


44. Ramalingam VS, Sinnakirouchenan R, Thappa DM: Malignant transformation of actinic keratoses to squamous cell carcinoma in an albino. Indian J Dermatol; 2009;54(1):46-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of actinic keratoses to squamous cell carcinoma in an albino.
  • He was diagnosed to have oculocutaneous albinism with actinic keratoses, with multiple squamous cell carcinomas (with metastatic deposits in the right inguinal region) and cutaneous horns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1989 Nov;125(11):1583-6 [2684028.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Arch Dermatol. 2003 Sep;139(9):1216-7 [12975172.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):920-3 [9041154.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):66-70 [12533168.001]
  • [Cites] J Am Acad Dermatol. 1995 Apr;32(4):653-8 [7896957.001]
  • (PMID = 20049269.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2800870
  • [Keywords] NOTNLM ; Albinism / actinic keratoses / cutaneous horns / squamous cell carcinomas
  •  go-up   go-down


45. Burnett TJ, English JC 3rd, Ferris LK: Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses. J Drugs Dermatol; 2010 Aug;9(8):1022-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses.
  • Food and Drug Administration (FDA) to treat actinic keratoses, non-facial superficial basal cell carcinomas and genital warts.
  • The authors report the case of a 56-year-old female who developed subacute cutaneous lupus erythematosus (SCLE), as well as severe autoimmune retinitis following a vigorous response to imiquimod 5% cream that was prescribed to treat actinic keratoses.
  • [MeSH-minor] Administration, Cutaneous. Autoimmune Diseases / chemically induced. Female. Humans. Keratosis, Actinic / drug therapy. Middle Aged. Retinitis / chemically induced. Retinitis / immunology. Severity of Illness Index

  • Genetic Alliance. consumer health - Cutaneous Lupus Erythematosus.
  • Genetic Alliance. consumer health - Lupus.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684157.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


46. Ulrich M, Maltusch A, Rius-Diaz F, Röwert-Huber J, González S, Sterry W, Stockfleth E, Astner S: Clinical applicability of in vivo reflectance confocal microscopy for the diagnosis of actinic keratoses. Dermatol Surg; 2008 May;34(5):610-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical applicability of in vivo reflectance confocal microscopy for the diagnosis of actinic keratoses.
  • BACKGROUND: In vivo reflectance confocal microscopy (RCM) has been used for evaluation of the morphologic features of nonmelanoma skin cancer.
  • The application of RCM for diagnosis of basal cell carcinoma has been reported; however, the evaluation of actinic keratoses (AKs) has only been the subject of preliminary studies.
  • STUDY GOAL: The goal of this study was to evaluate the applicability of RCM in the diagnosis of AK in correlation with routine histology.
  • MATERIALS AND METHODS: Forty-four Caucasians with a minimum of one AK participated in this study.
  • RCM features of AK included parakeratosis, architectural disarray, and keratinocyte pleomorphism.
  • The presence of architectural disarray and cellular pleomorphism appeared to be the best predictor of AK.
  • CONCLUSION: In summary, RCM may be a promising technology for the noninvasive detection of AK and as adjunct tool to clinical diagnosis and monitoring.
  • [MeSH-major] Epidermis / pathology. Keratosis / pathology. Microscopy, Confocal / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261097.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Smits T, Moor AC: New aspects in photodynamic therapy of actinic keratoses. J Photochem Photobiol B; 2009 Sep 4;96(3):159-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New aspects in photodynamic therapy of actinic keratoses.
  • Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) or its methyl ester (MAL) is a very effective method to treat actinic keratosis (AK).
  • [MeSH-major] Keratosis, Actinic / drug therapy. Photochemotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19592269.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / delta-aminolevulinic acid methyl ester; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 132
  •  go-up   go-down


48. Venna SS, Lee D, Stadecker MJ, Rogers GS: Clinical recognition of actinic keratoses in a high-risk population: how good are we? Arch Dermatol; 2005 Apr;141(4):507-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical recognition of actinic keratoses in a high-risk population: how good are we?
  • BACKGROUND: Actinic keratoses (AKs) are dysplastic epidermal lesions considered to be potential precursors of squamous cell carcinoma.
  • High interobserver variation exists among dermatologists for the diagnosis of AKs.
  • Previous studies of the positive predictive value of the diagnosis of AKs have yielded rates as high as 94%.
  • CONCLUSIONS: The positive predictive value of 74% for the diagnosis of AKs in this study is substantially lower than that of 2 previous studies, suggesting that physicians may be misdiagnosing many patients with classic features of AKs.
  • [MeSH-major] Keratosis / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837871.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Gholam P, Denk K, Sehr T, Enk A, Hartmann M: Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J Am Acad Dermatol; 2010 Aug;63(2):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses.
  • BACKGROUND: Topical photodynamic therapy is a good treatment option for extensively photodamaged skin with multiple actinic keratoses.
  • All patients had multiple actinic keratoses on the face, scalp, or back of hands and received an extensive treatment of the complete photodamaged area in our dermatologic outpatient department between February and May 2009.
  • [MeSH-major] Aminolevulinic Acid / adverse effects. Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Pain / etiology. Photochemotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • [CommentIn] J Am Acad Dermatol. 2011 Jul;65(1):201-2 [21679812.001]
  • (PMID = 20538367.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 0 / methyl 5-aminolevulinate; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


50. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC: Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol; 2005 Dec;53(6):966-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin.
  • BACKGROUND: Although animal studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, may protect against cutaneous squamous cell carcinoma (SCC) and actinic keratoses (AKs), possible effects on keratinocytic cancers in humans are unknown.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Carcinoma, Squamous Cell / prevention & control. Keratosis / prevention & control. Photosensitivity Disorders / prevention & control. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310056.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


51. Rossi R, Calzavara-Pinton PG, Giannetti A, Peserico A, Santucci M, Vena GA, Lotti T: Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol; 2009 Dec;144(6):713-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Italian guidelines and therapeutic algorithm for actinic keratoses.
  • The prevalence of actinic keratosis (AK) continues to rise among white people throughout the world and it is necessary to increase the level of attention paid to it from a diagnostic and a preventive point of view.
  • Today, AK must be considered an in situ squamous cell carcinoma and as such, must be managed using one of the available approved therapeutic alternatives.
  • [MeSH-major] Keratosis, Actinic / therapy. Practice Guidelines as Topic. Precancerous Conditions / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / prevention & control. Cryotherapy. Curettage. Dermatologic Agents / therapeutic use. Disease Progression. Electrocoagulation. Female. Humans. Italy / epidemiology. Laser Therapy. Male. Middle Aged. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / prevention & control. Phototherapy. Prevalence. Risk Factors. Sunscreening Agents. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907409.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Sunscreening Agents
  •  go-up   go-down


52. Menter A, Vamvakias G, Jorizzo J: One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. Cutis; 2008 Jun;81(6):509-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses.
  • Actinic keratoses (AKs) are common in fair-skinned individuals with a history of chronic and excessive sun exposure and may progress to squamous cell carcinoma (SCC).
  • The efficacy and tolerability of 1-week treatment using microsponge-based fluorouracil cream 0.5% were analyzed in 356 participants with AK lesions.
  • One-week treatment with once-daily fluorouracil cream 0.5% was significantly more effective than vehicle control in reducing AK lesions and in achieving complete clearance (P<.001).
  • Extending treatment for up to 4 weeks will further improve AK lesion clearance rates.
  • [MeSH-major] Fluorouracil / administration & dosage. Immunosuppressive Agents / administration & dosage. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666394.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Immunosuppressive Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 27
  •  go-up   go-down


53. Tierney EP, Eide MJ, Jacobsen G, Ozog D: Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cosmet Laser Ther; 2008 Jun;10(2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes.
  • BACKGROUND: While there are many available treatments for actinic keratoses (AKs), patient-preferred treatment options remain undefined.
  • [MeSH-major] Keratosis / drug therapy. Patient Satisfaction. Photochemotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569260.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


54. McBride P, Neale R, Pandeya N, Green A: Sun-related factors, betapapillomavirus, and actinic keratoses: a prospective study. Arch Dermatol; 2007 Jul;143(7):862-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sun-related factors, betapapillomavirus, and actinic keratoses: a prospective study.
  • OBJECTIVE: To examine prospectively the relationship among sun exposure, Betapapillomavirus, and development of actinic keratoses.
  • MAIN OUTCOME MEASURES: Prevalence of actinic keratoses in March 2003 after 7 years of follow-up.
  • RESULTS: Beyond the known determinants of multiple actinic keratoses, namely, advanced age, male sex, fair skin, and lifetime occupational sun exposure, Betapapillomavirus infection was associated with having more than 10 actinic keratoses (odds ratio, 1.8; 95% confidence interval, 0.7-4.4).
  • However, Betapapillomavirus positivity led to a significant 13-fold increase in the risk of actinic keratoses among those 60 years or older, a nearly 6-fold increase in risk when combined with fair skin color, and a doubling in risk of actinic keratoses when combined with high sun exposure, recent or cumulative, compared with those who had neither Betapapillomavirus infection nor the respective risk factor of interest.
  • CONCLUSIONS: Although the presence of Betapapillomavirus DNA in eyebrow hair follicle cells had only a small independent association with actinic keratoses, Betapapillomavirus infection in combination with key risk factors increased the risk of actinic keratoses, which is consistent with a potentiation by Betapapillomavirus of the effect of established causal factors.
  • [MeSH-major] Betapapillomavirus / isolation & purification. Keratosis / epidemiology. Keratosis / virology. Sunlight / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638729.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


55. Paoli J, Halldin C, Ericson MB, Wennberg AM: Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol; 2008 Aug;33(5):559-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses.
  • BACKGROUND: Photodynamic therapy (PDT) is a first-line therapeutic option for skin areas with multiple actinic keratoses (AKs).
  • [MeSH-major] Facial Dermatoses / drug therapy. Keratosis / drug therapy. Keratosis, Actinic / drug therapy. Nerve Block / methods. Photochemotherapy / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801096.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Ulrich M, Forschner T, Röwert-Huber J, González S, Stockfleth E, Sterry W, Astner S: Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy. Br J Dermatol; 2007 May;156 Suppl 3:47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy.
  • BACKGROUND: Clinical differentiation between actinic keratosis (AK) and disseminated superficial actinic porokeratosis (DSAP) may pose a significant challenge, and histological evaluation is often also required for diagnosis.
  • Distinct morphological features can be distinguished upon histopathological examination, but the use of non-invasive tools, such as reflectance confocal microscopy (RCM), may be an eligible alternative for confirmation of diagnosis.
  • OBJECTIVES: The aim of this study was to determine the relevant RCM criteria for the identification of disseminated superficial actinic porokeratoses (DSAPs) and to define distinguishing criteria for DSAPs compared with actinic keratosis (AKs).
  • PATIENTS/METHODS: A total of 20 patients with a clinical diagnosis of AK or DSAP were included in this study.
  • RESULTS: Cellular and nuclear atypia, inflammation, spongiosis, parakeratosis and changes in epidermal architecture were present in both lesion types (i.e.
  • However, further studies are warranted to assess the sensitivity and specificity of RCM in the diagnosis of DSAP.
  • [MeSH-major] Keratosis / pathology. Porokeratosis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Feasibility Studies. Humans. Microscopy, Confocal / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488407.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


57. Bartels P, Yozwiak M, Einspahr J, Saboda K, Liu Y, Brooks C, Bartels H, Alberts DS: Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry. Anal Quant Cytol Histol; 2009 Dec;31(6):355-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry.
  • OBJECTIVE: To determine whether low-dose topical applications of difluoromethylornithine (DFMO) with or without Triamcinolone (Fougena, Melville, New York, U.S.A.) to moderately sun-damaged skin with actinic skin keratoses are efficacious.
  • Participant eligibility included evidence of at least 2 actinic keratoses on each posterolateral forearm as well as moderate to severe evidence of sun-damaged skin, as evaluated by a board certified dermatologist.
  • Two specific measures of end point evaluation were computed, including the percentage of nuclei with high values of nuclear abnormality and the reduction of the percentage of nuclei assigned by a discriminant function to the baseline data set.
  • All 3 active interventions, including low-dose topical DFMO, topical Triamcinolone and topical DFMO + Triamcinolone, led to statistically significant reductions of both the number of nuclei with high nuclear abnormality as well as the number of nuclei assigned to the baseline data set.
  • CONCLUSION: The low-dose, topical drug interventions were all effective in reducing skin biopsy nuclear abnormality by a statistically significant 15-20%, whereas there was no evidence of a double placebo effect by karyometric assessment.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRIAMCINOLONE .
  • Hazardous Substances Data Bank. Eflornithine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Apr;57(4 Suppl 1):129-31 [11295610.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):300-12 [11531145.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Aug;24(4):185-97 [12199319.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1875-80 [15041701.001]
  • [Cites] Cytometry. 1986 Sep;7(5):467-74 [3757694.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Oct;20(5):407-16 [9801759.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Apr;29(2):63-70 [17484269.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1689-95 [18583468.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Dec;30(6):316-22 [19160696.001]
  • [Cites] Anal Quant Cytol Histol. 2009 Feb;31(1):17-25 [19320189.001]
  • (PMID = 20698351.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / Lipids; 0 / Ointment Bases; 1ZK20VI6TY / Triamcinolone; 8036-49-5 / eucerin; ZQN1G5V6SR / Eflornithine
  • [Other-IDs] NLM/ NIHMS586544; NLM/ PMC4038432
  •  go-up   go-down


58. Schlaak M, Simon JC: Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid--pilot study. J Dtsch Dermatol Ges; 2010 Mar;8(3):174-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid--pilot study.
  • BACKGROUND: Actinic keratoses (AK) are carcinomas in situ and can progress to invasive squamous cell carcinomas.
  • Treatment of actinic keratoses can be achieved by physical ablation, chemotherapeutic agents, immunomodulators or photodynamic therapy.
  • Overall 66 actinic keratoses were treated with 5-FU (0.5%) and salicylic acid (10%) for 4 weeks (3 times per week).
  • RESULTS: After 12 weeks complete response of 47 AK (77%), partial response of 13 AK (21%) and non-response of 1 AK (2%) were achieved.
  • [MeSH-major] Fluorouracil / administration & dosage. Keratosis, Actinic / drug therapy. Salicylic Acid / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. SALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19889001.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Drug Combinations; 0 / Immunosuppressive Agents; O414PZ4LPZ / Salicylic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Sellheyer K, Bergfeld WF: Differences in biopsy techniques of actinic keratoses by plastic surgeons and dermatologists: a histologically controlled pilot study. Arch Dermatol; 2006 Apr;142(4):455-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in biopsy techniques of actinic keratoses by plastic surgeons and dermatologists: a histologically controlled pilot study.
  • OBJECTIVE: To compare differences in biopsy techniques of actinic keratoses between dermatologists and plastic surgeons.
  • Intervention We reexamined the histopathologic slides of 405 actinic keratosis biopsy specimens obtained by plastic surgeons and dermatologists from January 1, 1992, through May 31, 2002.
  • We were specifically interested in the type of biopsy technique (shave, punch, or excisional biopsy) used for the surgical management of actinic keratoses by both groups of physicians.
  • In contrast, shave biopsies of actinic keratoses were performed by plastic surgeons in only 32.4% of the cases, compared with 89.4% by dermatologists.
  • Only 1 (0.5%) of the 198 dermatopathology request forms submitted by the plastic surgeons mentioned actinic keratosis, compared with 82 (39.6%) of 207 histopathologic evaluation requests submitted by dermatologists.
  • CONCLUSIONS: The predominance of excisional biopsies of actinic keratoses by plastic surgeons may be related to a different ability in the clinical recognition of actinic keratoses compared with that of dermatologists.
  • [MeSH-major] Biopsy / methods. Clinical Competence. Dermatology / standards. Keratosis / pathology. Practice Patterns, Physicians' / statistics & numerical data. Surgery, Plastic / standards

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Oct;142(10):1363-4 [17043200.001]
  • (PMID = 16618864.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Huyke C, Laszczyk M, Scheffler A, Ernst R, Schempp CM: [Treatment of actinic keratoses with birch bark extract: a pilot study]. J Dtsch Dermatol Ges; 2006 Feb;4(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of actinic keratoses with birch bark extract: a pilot study].
  • Therefore, birch bark extract may be effective in the treatment of actinic keratoses.
  • METHODS: Twenty-eight patients with actinic keratoses were enrolled in this prospective, non-randomized pilot study.
  • CONCLUSION: In this pilot study, a standardized birch bark extract was effective in the treatment of actinic keratoses.
  • Birch bark ointment may be a new therapeutic option for actinic keratoses.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503940.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ointments; 0 / Plant Extracts
  •  go-up   go-down


61. Plasmeijer EI, Neale RE, de Koning MN, Quint WG, McBride P, Feltkamp MC, Green AC: Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma. Cancer Res; 2009 Dec 1;69(23):8926-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma.
  • We assessed the extent to which betaPV infections persisted long-term in a subtropical Australian community and whether betaPV persistence is positively associated with actinic keratoses, precursor for SCC.
  • Hair samples were tested for the presence of DNA from 25 different betaPV types and assessed in relation to actinic keratosis presence in 2007.
  • After accounting for actinic keratoses at baseline, persistence of betaPV DNA resulted in a 1.4-fold (95% confidence interval, 1.0-1.9) increase in risk of having actinic keratoses on the face in 2007.
  • In conclusion, persistent betaPV infections in this population were associated with an increased occurrence of actinic keratosis.
  • [MeSH-major] Betapapillomavirus / isolation & purification. Carcinoma, Squamous Cell / virology. Cell Transformation, Viral. Keratosis, Actinic / virology. Papillomavirus Infections / pathology. Skin Neoplasms / virology


62. Del Rosso JQ, Sofen H, Leshin B, Meng T, Kulp J, Levy S: Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses. J Clin Aesthet Dermatol; 2009 Apr;2(4):20-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses.
  • OBJECTIVE: Safety of multiple 16-week courses of imiquimod applied to large areas (>25 cm(2)) of skin with actinic keratoses.
  • DESIGN: Subjects applied 1 to 6 packets two times per week for 16 weeks; if actinic keratoses were persistent at two months post-treatment, up to two additional courses could be administered within the 18-month study period.
  • PARTICIPANTS: Adults with >/=4 actinic keratoses on the head, torso, and/or extremities.
  • CONCLUSION: Multiple 16-week courses of imiquimod to treat actinic keratoses were well tolerated and significantly decreased lesions in subjects with extensive actinic keratoses.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S139-48 [18410800.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):25-8 [10607354.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):133-41 [17501955.001]
  • [Cites] J Transl Med. 2007;5:7 [17257431.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):72-8 [16403097.001]
  • [Cites] Br J Dermatol. 2004 Dec;151(6):1150-9 [15606509.001]
  • [Cites] Semin Cutan Med Surg. 1999 Mar;18(1):3-14 [10188837.001]
  • [Cites] J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):223-42 [8708026.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):455-64 [7947197.001]
  • [Cites] Br J Dermatol. 1986 Dec;115(6):649-55 [3801305.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Eur J Dermatol. 2003 Nov-Dec;13(6):515-23 [14721768.001]
  • [Cites] Cell Immunol. 2002 Jul-Aug;218(1-2):74-86 [12470615.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):138-50 [10863242.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):265-8 [17512087.001]
  • (PMID = 20729935.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923947
  •  go-up   go-down


63. Szeimies RM, Karrer S, Bäcker H: [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma]. Hautarzt; 2005 May;56(5):430-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].
  • [Transliterated title] Therapieoptionen bei epithelialen Hauttumoren Aktinische Keratosen, Morbus Bowen, spinozelluläres Karzinom und Basalzellkarzinom.
  • In the following article different therapeutic approaches for actinic keratoses, Bowen's disease, basal cell carcinoma and squamous cell carcinoma are presented and analysed.
  • [MeSH-major] Risk Assessment / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Bowen's Disease / diagnosis. Bowen's Disease / therapy. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Cryotherapy / methods. Curettage / methods. Humans. Keratosis / diagnosis. Keratosis / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815888.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


64. Harvie SE: Aminolevulinic acid and photodynamic combination therapy in the treatment of actinic keratoses: caring for the patient. Dermatol Nurs; 2007 Feb;19(1):31-4, 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminolevulinic acid and photodynamic combination therapy in the treatment of actinic keratoses: caring for the patient.
  • Combination therapy with 5-aminolevulinic acid and photodynamic therapy is fast becoming the treatment of choice in treating precancerous skin lesions such as actinic keratoses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330552.001).
  • [ISSN] 1060-3441
  • [Journal-full-title] Dermatology nursing
  • [ISO-abbreviation] Dermatol Nurs
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 42VZT0U6YR / Heme; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 21
  •  go-up   go-down


65. Seckin D, Cerman AA, Yildiz A, Ergun T: Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report. J Drugs Dermatol; 2009 May;8(5):451-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report.
  • OBJECTIVE: To determine whether actinic keratoses may benefit from the antiproliferative and prodifferentiative effects of topical vitamin D.
  • The total number of actinic keratoses (AKs), diameters and total scores of the target lesions were determined at each visit.
  • CONCLUSION: Topical calcipotriol may show promise in the treatment of actinic keratoses.
  • [MeSH-major] Calcitriol / analogs & derivatives. Dermatologic Agents / administration & dosage. Dermatologic Agents / therapeutic use. Keratosis, Actinic / drug therapy

  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537367.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 143NQ3779B / calcipotriene; FXC9231JVH / Calcitriol
  •  go-up   go-down


66. Berlin JM, Rigel DS: Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol; 2008 Jul;7(7):669-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery.
  • BACKGROUND: Actinic keratoses are increasingly common skin lesions that are evaluated and treated by dermatologists on a daily basis.
  • It is estimated that more than 90% of actinic keratoses in the US are treated by destructive therapies, such as cryosurgery.
  • A total of 714 subjects who had a clinical diagnosis of actinic keratosis with between 5 and 15 lesions contained in a target area such as the forehead, scalp, and hands were enrolled in the study.
  • CONCLUSIONS: With the increased prevalence of actinic keratoses, it is important to consider and evaluate emerging therapeutic options.
  • The sequential treatment with cryosurgery followed by diclofenac sodium 3% gel for 90 days is well tolerated and can provide a therapeutic modality that may provide patients with actinic keratoses a more successful outcome than monotherapy with cryosurgery by effectively treating clinical and subclinical lesions.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cryosurgery. Diclofenac / therapeutic use. Keratosis / drug therapy. Keratosis / surgery

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18664159.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


67. Sachs DL, Kang S, Hammerberg C, Helfrich Y, Karimipour D, Orringer J, Johnson T, Hamilton TA, Fisher G, Voorhees JJ: Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis. Arch Dermatol; 2009 Jun;145(6):659-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis.
  • OBJECTIVE: To examine clinical and molecular changes after topical fluorouracil treatment of photodamaged human facial skin for actinic keratoses.
  • PATIENTS: Twenty-one healthy volunteers, 56 to 85 years old, with actinic keratoses and photodamage.
  • MAIN OUTCOME MEASURES: Gene and protein expression of molecular effectors of epidermal injury, inflammation, and extracellular matrix remodeling 24 hours after fluorouracil treatment; clinical improvement measured by evaluators, photography, and patient questionnaires.
  • RESULTS: One day after the final fluorouracil treatment, gene expression of the effectors of epidermal injury (keratin 16), inflammation (interleukin 1beta), and extracellular matrix degradation (matrix metalloproteinases 1 and 3) was significantly increased.
  • Actinic keratoses and photoaging were statistically significantly improved.
  • CONCLUSIONS: Topical fluorouracil causes epidermal injury, which stimulates wound healing and dermal remodeling resulting in improved appearance.
  • [MeSH-major] Fluorouracil / therapeutic use. Keratosis, Actinic / drug therapy. Skin Aging / drug effects


68. Shaffelburg M: Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol; 2009 Jan;8(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
  • BACKGROUND: Field-directed therapies for actinic keratosis include photodynamic therapy and imiquimod.
  • METHODS: The entire face of adults with > or =10 facial actinic keratoses were treated with photodynamic therapy with aminolevulinic acid 20% at baseline and at month 1.
  • CONCLUSIONS: Photodynamic therapy followed by imiquimod was well tolerated and improved reduction of actinic keratoses.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180894.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Photosensitizing Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


69. Han A, Penrose C, Goldsmith A, Marmur ES: Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments. J Drugs Dermatol; 2010 Jul;9(7):864-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-based considerations in the treatment of actinic keratoses: utilizing combination or sequential therapy with 5-fluorouracil cream and destructive treatments.
  • Actinic keratoses are premalignant lesions that increase in frequency with each decade of life and have the potential to progress to squamous cell carcinoma.
  • The following case-based review represents typical situations where multiple treatments were combined to manage actinic keratosis, squamous cell carcinoma and basal cell carcinoma in patients over an extended treatment period.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Keratosis, Actinic / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677546.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


70. Kulp J, Levy S, Fein MC, Adams M, Furst J, Meng TC: Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp. Arch Dermatol Res; 2010 Sep;302(7):539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
  • Imiquimod 3.75% cream is a topical formulation of imiquimod intended for daily application to treat actinic keratoses of the entire face or balding scalp.
  • Nineteen subjects with actinic keratoses applied two packets of imiquimod 3.75% cream (18.75 mg imiquimod total) once daily for 21 days to a treatment area approximately 200 cm(2) in size on the face and/or balding scalp.
  • [MeSH-major] Aminoquinolines / pharmacokinetics. Face / pathology. Keratosis, Actinic / drug therapy. Scalp / pathology. Skin / drug effects

  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204654.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


71. Toll A, Salgado R, Yébenes M, Martín-Ezquerra G, Gilaberte M, Baró T, Solé F, Alameda F, Espinet B, Pujol RM: Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Exp Dermatol; 2010 Feb;19(2):151-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas.
  • Epidermal growth factor receptor (EGFR) gene amplification and protein overexpression are common in several cancers.
  • EGFR status has seldom been studied in cutaneous squamous carcinomas (SCCs), or their precursors, actinic keratoses (AKs).
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Genes, erbB-1. Keratosis, Actinic / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Gene Dosage. Humans. Immunohistochemistry. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156290.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


72. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H, European Skin Academy: Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol; 2008 Nov-Dec;18(6):651-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a treatment algorithm for actinic keratoses: a European Consensus.
  • Actinic keratoses (AKs) are lesions caused by chronic UV radiations that have the potential to progress to invasive SCCs.
  • The prevalence of AK is increasing worldwide, and although there are a variety of treatment modalities, along with a number of published guidelines, there is a lack of advice on treatment recommendations for AK in clinical practice.
  • There are also considerable variations in the care of patients with AK in Europe, and so the Skin Academy (a group of leading experts in the field of dermatology and skin cancer) formed to discuss best practice in the treatment of AK.
  • The new AK Treatment Algorithm described in this paper comprises 5 key, decision making steps, which are simple and allow the flexibility to reflect cultural differences between and within countries.
  • It offers, for the first time, a summary of European best practice recommendations for the treatment of AK.
  • [MeSH-major] Keratosis, Actinic / therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955209.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


73. Hughes MC, Williams GM, Fourtanier A, Green AC: Food intake, dietary patterns, and actinic keratoses of the skin: a longitudinal study. Am J Clin Nutr; 2009 Apr;89(4):1246-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Food intake, dietary patterns, and actinic keratoses of the skin: a longitudinal study.
  • BACKGROUND: Actinic keratoses (AKs) are premalignant actinic tumors of the skin.
  • The relative ratio (RR) of AK counts in 1996 relative to 1992 was compared across increasing intakes of 26 food groups, and for 3 dietary patterns identified by principal components analysis, with the use of generalized linear models with negative binomial distribution, allowing for repeated measures.
  • RESULTS: AK acquisition decreased by 28% (RR: 0.72; 95% CI: 0.55, 0.95) among the highest consumers of oily fish (average of one serving every 5 d) compared with those with minimal intake.
  • There was no consistent association of dietary pattern with AK acquisition.
  • CONCLUSION: Moderate intake of oily fish and of wine may decrease the acquisition of AKs and thus complement sun protection measures in the control of actinic skin tumors.
  • [MeSH-major] Diet. Keratosis, Actinic / epidemiology. Seafood. Sunlight / adverse effects. Wine

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19244366.001).
  • [ISSN] 1938-3207
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Balkrishnan R, Cayce KA, Kulkarni AS, Orsagh T, Gallagher JR, Richmond D, Feldman SR: Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat; 2006;17(3):162-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study.
  • OBJECTIVES: Actinic keratoses (AKs) are common skin lesions with the potential to progress to squamous cell carcinoma.
  • This study examined which AK therapy was preferred among dermatologists and primary care physicians (PCPs), as well as potential determinants of therapeutic selection.
  • METHODS: A random national sample of 534 dermatologists and PCPs selected from the American Medical Association database completed AK questionnaires.
  • The final sample included 1184 AK patients treated by dermatologists and 559 AK patients treated and/or referred by PCPs.
  • RESULTS: Patients who had new and recurring lesions as well as patients who had a mean duration of more than a year since the last AK episode treatment (all p<0.05) were more likely to receive pharmacotherapy.
  • CONCLUSIONS: This study identifies several patient and physician factors associated with treatment preference and related outcomes in patients being treated for AK.
  • [MeSH-major] Dermatology. Keratosis / therapy. Outcome Assessment (Health Care). Practice Patterns, Physicians' / statistics & numerical data. Primary Health Care. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854758.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratolytic Agents
  •  go-up   go-down


75. Kleinpenning MM, van de Kerkhof PC, Gerritsen RM: The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp. J Dermatolog Treat; 2010 Jul;21(4):252-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp.
  • INTRODUCTION: Since actinic keratoses (AKs) often appear in areas with field cancerization, photodynamic therapy (PDT) may have significant advantages over the standard treatment options.
  • RESULTS: Complete clearance was reached in patients with a moderate degree of actinic damage, whereas a severe degree of field cancerization demonstrated only partial clearance.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Keratosis, Actinic / pathology. Photochemotherapy / methods. Precancerous Conditions / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832288.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


76. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S: Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg; 2006 Oct;32(10):1261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation.
  • BACKGROUND: The ability to clinically diagnose actinic keratoses (AKs) lesions has been taken for granted for some time.
  • OBJECTIVE: The objective was to characterize the histopathology of clinically diagnosed AK lesions in the study population.
  • RESULTS: Clinical diagnosis and histopathologic findings agreed in 91% (246/271) of the lesions biopsied.
  • CONCLUSIONS: In this study, about 1 in 25 clinically diagnosed AK lesions identified by board-certified dermatologist investigator(s) were occult early-stage squamous cell carcinomas on histologic assessment, a fact surmised by the medical community that until now had not been well quantified.
  • These findings should be considered when clinicians decide how to treat and manage AK patients.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034376.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group: Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer; 2009 Jun 1;115(11):2523-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.
  • BACKGROUND: Actinic keratoses (AKs) are established as direct precursors of squamous cell carcinoma (SCC), but there is significant controversy regarding the rate at which AKs progress to SCC.
  • The authors of this report studied a high-risk population to estimate the risk of progression of AK to SCC and to basal cell carcinoma (BCC) and the risk of spontaneous regression of untreated AKs.
  • These photographs were used later to map and track the presence, absence, or biopsy of each AK across visits.
  • The risk of progression of AK to primary SCC (invasive or in situ) was 0.60% at 1 year and 2.57% at 4 years.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Disease Progression. Keratosis, Actinic / pathology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382202.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01AR49342; United States / NCI NIH HHS / CA / R01CA106592; United States / NCI NIH HHS / CA / R01CA106807; United States / NCI NIH HHS / CA / R25CA087972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Investigator] Weinstock MA; Marcolivio K; Weinstock M; Bingham S; DiGiovanna J; Hall R; Naylor M; Taylor JR; Vertrees J; White C; Hall R; Hannah D; Eilers D; Liang T; Sakla N; Kreuger A; Cole G; Jeffes E; Labrador T; Taylor JR; Kirsner R; Kerri JE; Falabela AG; Givens M; Naylor M; Benson MB; Perry L; Kalivas J; Yanni C; Targovnik S; Austin J; Collier S; Collins JF; Bingham S; Calvert B; Connor P; Crigler C; Davis D; Grubb P; Kelly J; Kirk G; Lawson K; Linzy L; Palmer L; Rhoads M; Sather M; Copeland E; Fye C; Gagne W; de Naranjo PG; Messick C; Vertrees J; Piepkorn M; White C; Lew R; Braverman I; Cole B; Kalish R; McLean D; Thiers B
  •  go-up   go-down


78. Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV: Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J Biomed Opt; 2010 Sep-Oct;15(5):051607
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate.
  • Topical 5-aminolevulinic acid (ALA) is widely used in photodynamic therapy (PDT) of actinic keratoses (AK), a type of premalignant skin lesion.
  • Our objective is to study the kinetics of protoporphyrin IX (PpIX) accumulation in AK after short contact ALA and relate this to erythemal responses.
  • Using a noninvasive dosimeter, PpIX fluorescence measurements (5 replicates) were taken at 20-min intervals for 2 h following ALA application, in 63 AK in 20 patients.
  • We conclude that significant amounts of PpIX are produced in all AK lesions by 2 h.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis, Actinic / drug therapy. Keratosis, Actinic / metabolism. Photochemotherapy / methods. Protoporphyrins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lasers Surg Med. 2000;26(1):76-82 [10637006.001]
  • [Cites] J Am Acad Dermatol. 2009 Dec;61(6):1033-43 [19925929.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):983-90 [11359385.001]
  • [Cites] Acta Derm Venereol. 2001 Aug-Sep;81(4):246-9 [11720169.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Dermatol Surg. 2004 Jul;30(7):1054-61 [15209801.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):305-9 [16433801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1211-20 [16504761.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):5-14 [17126737.001]
  • [Cites] Dermatol Clin. 2007 Jan;25(1):119-20 [17126750.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Adv Dermatol. 2006;22:219-58 [17249304.001]
  • [Cites] Photochem Photobiol. 2007 May-Jun;83(3):738-48 [17576383.001]
  • [Cites] J Drugs Dermatol. 2007 Dec;6(12):1197-202 [18189059.001]
  • [Cites] J Drugs Dermatol. 2008 Nov;7(11):1033-7 [19110733.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3333-43 [19447864.001]
  • [Cites] Photochem Photobiol. 2000 Oct;72(4):569-74 [11045731.001]
  • (PMID = 21054081.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA084203
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  • [Other-IDs] NLM/ PMC2955723
  •  go-up   go-down


79. Babilas P, Travnik R, Werner A, Landthaler M, Szeimies RM: Split-face-study using two different light sources for topical PDT of actinic keratoses:non-inferiority of the LED system. J Dtsch Dermatol Ges; 2008 Jan;6(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split-face-study using two different light sources for topical PDT of actinic keratoses:non-inferiority of the LED system.
  • BACKGROUND: Photodynamic therapy (PDT) with 5-amino-4-oxo-pentanoate (methylaminolevulinate, MAL) is an effective and safe treatment option for actinic keratoses.
  • METHODS: Topical ALA-PDT was administered to 17 patients whose actinic ker-atoses (n = 131) were symmetrically distributed and suitable for a two-side comparison.
  • RESULTS: Six months following treatment there was no significant difference between the infiltration and keratosis scores in both treatment regimes (p = 0.812).
  • CONCLUSIONS: LEDA-based MAL-PDT is an effective alternative for the treatment of atinic keratoses.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis / drug therapy. Lighting / instrumentation. Lighting / methods. Photochemotherapy / methods. Photosensitivity Disorders / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17995967.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


80. Bernard P, Dupuy A, Sasco A, Brun P, Duru G, Nicoloyannis N, Grob JJ: Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey. Dermatology; 2008;216(3):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey.
  • BACKGROUND: Most actinic keratoses (AKs) and a number of basal cell carcinomas (BCCs) cannot be assessed by pathological records.
  • When extrapolating, the medical load in France was estimated at 248,000 and 693,000 consultations/year leading to a clinical diagnosis of BCC and AK, respectively.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Keratosis / epidemiology. Skin Neoplasms / epidemiology. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182809.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


81. Stough D, Bucko AD, Vamvakias G, Rafal ES, Davis SA: Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: an 18-month open-label study. Cutis; 2010 May;85(5):267-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorouracil cream 0.5% for actinic keratoses on multiple body sites: an 18-month open-label study.
  • This prospective 18-month, open-label, multicenter study assessed the long-term safety and efficacy of fluorouracil cream 0.5% in 277 participants with multiple actinic keratoses (AKs) on the face/anterior scalp and other body sites.
  • After TC1 (week 8), the number of AK lesions was significantly reduced on the face/anterior scalp and all other treated body sites (P < .0001).
  • This study indicates that fluorouracil cream 0.5% with a patented microsponge delivery system was well-tolerated and effective in treating and preventing recurrence of AK lesions up to 18 months after initial treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Keratosis, Actinic / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540418.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


82. Mastrolonardo M: Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol; 2009 Jan;34(1):33-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses.
  • This paper reviews retrospectively the results obtained in a case series of multiple refractory actinic keratoses (AKs), treated sequentially with topical diclofenac 3% gel followed by cryotherapy.
  • Significantly, during the post-treatment follow-up period, patients had no AK recurrences for an average of 10 months (range 6-20).
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Cryotherapy / methods. Diclofenac / administration & dosage. Keratosis, Actinic / therapy

  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616726.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


83. Dirschka T, Bierhoff E, Pflugfelder A, Garbe C: Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol; 2010 Mar;24(3):258-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses.
  • BACKGROUND: Actinic keratoses (AKs) are frequently diagnosed in dermatological patients.
  • OBJECTIVES: We investigated the effect of topical 3.0% diclofenac in 2.5% hyaluronic acid gel on AK.
  • Specimens were evaluated for histological type of AKs using the AK classification scheme suggested by Röwert-Huber et al. [(early) in situ squamous cell carcinoma type AK Grade I-III], number of mitoses per high-power field and expression of immunohistological markers.
  • A significant (P<0.001) downgrading of AK grade was observed.
  • [MeSH-major] Cell Transformation, Neoplastic / drug effects. Diclofenac / administration & dosage. Hyaluronic Acid / administration & dosage. Keratosis, Actinic / drug therapy. Precancerous Conditions / prevention & control. Skin / pathology. Skin Neoplasms / prevention & control
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Administration, Topical. Aged. Aged, 80 and over. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Disease Progression. Female. Follow-Up Studies. Gels. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709346.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gels; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


84. Gold MH: Therapeutic and aesthetic uses of photodynamic therapy part one of a five-part series: the use of photodynamic therapy in the treatment of actinic keratoses and in photorejuvenation. J Clin Aesthet Dermatol; 2008 Jul;1(2):32-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic and aesthetic uses of photodynamic therapy part one of a five-part series: the use of photodynamic therapy in the treatment of actinic keratoses and in photorejuvenation.
  • This was first seen in the treatment of nonhyperkeratotic actinic keratoses of the face and scalp where resolution of the actinic keratoses was achieved and a cosmetic improvement noted from the therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103321.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2989821
  •  go-up   go-down


85. Rishpon A, Kim N, Scope A, Porges L, Oliviero MC, Braun RP, Marghoob AA, Fox CA, Rabinovitz HS: Reflectance confocal microscopy criteria for squamous cell carcinomas and actinic keratoses. Arch Dermatol; 2009 Jul;145(7):766-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reflectance confocal microscopy criteria for squamous cell carcinomas and actinic keratoses.
  • OBJECTIVE: To identify criteria for the diagnosis of squamous cell carcinoma (SCC) and actinic keratosis (AK) by in vivo reflectance confocal microscopy (RCM).
  • DESIGN: Prospective RCM imaging of lesions suspected clinically and/or dermoscopically to be SCC or AK, followed by RCM assessment of the biopsy-proven SCCs and AKs.
  • Polygonal nucleated cells at the stratum corneum were seen in 3 SCCs (10%) and 1 AK (14%).
  • All 38 cases displayed an atypical honeycomb and/or a disarranged pattern of the spinous-granular layer of the epidermis; round nucleated cells were seen in the spinous-granular layer in 20 SCCs (65%) and 1 AK (14%).
  • CONCLUSIONS: An increasing frequency of abnormal RCM features can be observed across the spectrum of keratinocytic neoplasias.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis, Actinic / pathology. Skin Neoplasms / pathology


86. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM: Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer; 2009 Jan;7(1):20-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
  • Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in 2 patients treated with sorafenib (Lacouture et al), but the scope of this observation has not been evaluated.
  • The time to development of SCC or AK from the start of sorafenib was 9.3 months (median, 6.5 months; range, 0.9-43 months).
  • Ten of these 14 patients discontinued therapy with sorafenib: 7 patients as a result of disease progression, 2 patients as a result of nondermatologic toxicity, and 1 patient as a result of dermatologic toxicity.
  • CONCLUSION: These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK.
  • [MeSH-major] Benzenesulfonates / adverse effects. Carcinoma, Squamous Cell / chemically induced. Drug Eruptions / etiology. Keratosis, Actinic / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyridines / adverse effects. Skin Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Genitourin Cancer. 2009 Jan;7(1):9-10 [19213661.001]
  • (PMID = 19213663.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ NIHMS773866; NLM/ PMC4825856
  •  go-up   go-down


87. Einspahr JG, Xu MJ, Warneke J, Saboda K, Ranger-Moore J, Bozzo P, Duckett L, Goldman R, Lin P, Buckmeier J, Alberts DS: Reproducibility and expression of skin biomarkers in sun-damaged skin and actinic keratoses. Cancer Epidemiol Biomarkers Prev; 2006 Oct;15(10):1841-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducibility and expression of skin biomarkers in sun-damaged skin and actinic keratoses.
  • METHODS: Biopsies were collected from three groups: 78 subjects with sun damage on forearms, 33 with actinic keratosis (AK) on forearms, and 32 with previous squamous cell carcinoma.
  • RESULTS: We found significant differences in p53 and polyamines in forearms from the sun-damaged group (11.5 +/- 1.2% for p53, 65.5 +/- 1.9 nmol/g for putrescine, and 187.7 +/- 3.3 nmol/g for spermidine) compared with the group with sun damage plus AK (20.9 +/- 2.3% for p53, P = 0.0001; 81.7 +/- 3.9 nmol/g for putrescine, P = 0.0001; 209.4 +/- 8.2 nmol/g for spermidine, P < 0.06).
  • When lesion histology was considered, there was a stepwise significant increase in p53 in biopsies without characteristics of AK compared with early AK (P = 0.02) and AK (P = 0.0006) and a similar pattern for PCNA with the only significant difference between early AK and AK.
  • There was a stepwise increase in putrescine and spermidine in normal, sun-damaged forearm, forearm from subjects with AK, and the AK lesion itself (P < 0.0001).
  • [MeSH-major] Biomarkers / metabolism. Keratosis / etiology. Keratosis / metabolism. Proliferating Cell Nuclear Antigen / biosynthesis. Sunscreening Agents / therapeutic use. Tumor Suppressor Protein p53 / biosynthesis. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021352.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA27502
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biogenic Polyamines; 0 / Biomarkers; 0 / Proliferating Cell Nuclear Antigen; 0 / Sunscreening Agents; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


88. Gold MH: Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol; 2008 Jan;7(1):23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacoeconomic analysis of the treatment of multiple actinic keratoses.
  • Actinic keratosis (AK) is common and lesions may progress to squamous cell carcinoma.
  • This report provides a simple pharmacoeconomic analysis of 4 FDA-cleared therapies (imiquimod, diclofenac, 5-fluorouacil [5-FU], and ALA PDT) for AK given in combination with cryotherapy.
  • Among these 4 FDA-cleared therapies for multiple AK lesions, ALA PDT is the least expensive treatment and imiquimod is the most expensive treatment under the stated assumptions.
  • [MeSH-major] Cryotherapy / methods. Keratosis / therapy. Photochemotherapy / methods

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246694.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 144O8QL0L1 / Diclofenac; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  •  go-up   go-down


89. Stockfleth E, Kerl H, Guideline Subcommittee of the European Dermatology Forum: Guidelines for the management of actinic keratoses. Eur J Dermatol; 2006 Nov-Dec;16(6):599-606
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for the management of actinic keratoses.
  • [MeSH-major] Keratosis / therapy. Photosensitivity Disorders / therapy

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229598.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] France
  • [Chemical-registry-number] 144O8QL0L1 / Diclofenac; U3P01618RT / Fluorouracil
  •  go-up   go-down


90. Ostertag JU, Quaedvlieg PJ, Neumann MH, Krekels GA: Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp. Dermatol Surg; 2006 Feb;32(2):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses on the face and scalp.
  • BACKGROUND: Diffuse widespread actinic keratoses are difficult to treat, have a tendency toward higher recurrence rates, and therefore require ablative treatment.
  • OBJECTIVE: To evaluate patients who underwent laser resurfacing for widespread actinic keratoses with long-term follow-up for recurrence rates, time until new lesions occur, and the most common side effects.
  • METHODS: Retrospective case-control study from 25 patients who underwent laser resurfacing for widespread actinic keratoses on the scalp, forehead, or full face at our department.
  • The most common short- and long-term side effects were infections (12%), hypopigmentation (48%), hyperpigmentation (8%), acne (12%), milia (12%), scar formation (8%), and atrophic and/or easily bruised skin (20%).
  • CONCLUSION: Laser resurfacing is an effective treatment modality for diffuse widespread actinic keratoses with long-term recurrence-free intervals.
  • [MeSH-major] Keratosis / surgery. Laser Therapy. Precancerous Conditions / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442048.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E, Kerrouche N, Sorba V, Villemagne H, Rhodes LE: Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol; 2008 May;158(5):994-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities.
  • BACKGROUND: Methyl aminolaevulinate-photodynamic therapy (MAL-PDT) is an effective treatment in facial/scalp actinic keratosis (AK).
  • OBJECTIVES: The aims of this study were to compare efficacy, safety, cosmetic outcome and patient preference of MAL-PDT vs. cryotherapy in patients with AK at other locations.
  • Patients with nonhyperkeratotic AK were treated once with MAL-PDT and cryotherapy on either side of the body.
  • CONCLUSIONS: MAL-PDT showed inferior efficacy for treatment of non-face/scalp AK compared with cryotherapy.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Cryosurgery. Keratosis / drug therapy. Photochemotherapy / standards. Photosensitizing Agents / therapeutic use


92. Fariba I, Ali A, Hossein SA, Atefeh S, Atarzadeh Behbahan SA: Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol; 2006 Sep-Oct;72(5):346-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study.
  • BACKGROUND: Actinic keratoses (AKs) are premalignant skin lesions caused by excessive sun exposure.
  • AIMS: To explore the therapeutic efficacy of 3% diclofenac in 2.5% hyaluronan gel in the topical treatment of AK.
  • CONCLUSION: Considering the malignant potential of actinic keratoses and the importance of clearing them to prevent their transformation to squamous cell carcinoma, the efficacy of diclofenac gel seen in our study seems to be low.
  • This treatment may be useful for patients who do not tolerate other, more effective kinds of treatment for actinic keratoses.
  • [MeSH-major] Diclofenac / administration & dosage. Keratosis / drug therapy. Precancerous Conditions / drug therapy

  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050927.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Gels; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


93. Schmid-Wendtner MH, Wendtner CM: Intensified inflammatory reaction of actinic keratoses after single application of topical 5-fluorouracil in a patient treated with nilotinib for chronic myeloid leukemia. Dermatology; 2009;219(4):341-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified inflammatory reaction of actinic keratoses after single application of topical 5-fluorouracil in a patient treated with nilotinib for chronic myeloid leukemia.
  • Actinic keratoses frequently occur in sun-exposed areas of the skin and, today, a variety of therapeutic options are available, including topical application of 5-fluorouracil (5-FU).
  • We, therefore, discuss possible modes of action including other reports about different tyrosine kinase inhibitors which led to regression of aggravation of actinic keratoses.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Dermatologic Agents / therapeutic use. Fluorouracil / therapeutic use. Keratosis, Actinic / drug therapy. Keratosis, Actinic / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Pyrimidines / adverse effects

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19468201.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Dermatologic Agents; 0 / Pyrimidines; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Peters-Kennedy J, Scott DW, Miller WH Jr: Apparent clinical resolution of pinnal actinic keratoses and squamous cell carcinoma in a cat using topical imiquimod 5% cream. J Feline Med Surg; 2008 Dec;10(6):593-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent clinical resolution of pinnal actinic keratoses and squamous cell carcinoma in a cat using topical imiquimod 5% cream.
  • This case report describes a cat with actinic keratoses and squamous cell carcinoma of the pinnae.
  • These results suggest that topical imiquimod, although unproven, might be a therapeutic option or adjunct to therapy for cats with actinic keratoses and squamous cell carcinoma, especially those cats for whom surgery and radiation therapy are not an option.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417398.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


95. Serra-Guillen C, Hueso L, Nagore E, Vila M, Llombart B, Requena Caballero C, Botella-Estrada R, Sanmartin O, Alfaro-Rubio A, Guillen C: Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone. Br J Dermatol; 2009 Aug;161(2):353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone.
  • BACKGROUND: Photodynamic therapy (PDT) is an effective treatment for actinic keratoses, Bowen's disease and basal cell carcinoma.
  • METHODS: A controlled open clinical trial was conducted in 34 patients having multiple actinic keratoses in the frontal region treated with PDT.
  • [MeSH-major] Analgesia / methods. Cold Temperature. Facial Dermatoses / drug therapy. Keratosis, Actinic / drug therapy. Nerve Block / methods. Pain Management. Photochemotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438468.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Zeichner JA, Stern DW, Uliasz A, Itenberg S, Lebwohl M: Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol; 2009 Jan;60(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses.
  • BACKGROUND: Imiquimod 5% cream applied twice weekly for 16 weeks is effective for treating actinic keratoses but may be limited by local side effects.
  • CONCLUSION: Imiquimod 5% cream applied once weekly for 24 weeks was convenient for patients and resulted in improvement of actinic keratoses with minimal side effects.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Keratosis, Actinic / drug therapy

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937999.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Pharmaceutical Preparations; 99011-02-6 / imiquimod
  •  go-up   go-down


97. Huyke C, Reuter J, Rödig M, Kersten A, Laszczyk M, Scheffler A, Nashan D, Schempp C: Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges; 2009 Feb;7(2):128-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study.
  • BACKGROUND: Actinic keratoses (AK) are squamous cell carcinomas in situ and require treatment.
  • PATIENTS AND METHODS: In the prospective, randomized, monocentric phase 2a study 45 patients with < 10 AK were included and randomly assigned to one of the three treatment groups.
  • CONCLUSIONS: Betulin-based oleogel seems to be an effective novel approach in the topical treatment of actinic keratoses.
  • [MeSH-major] Keratosis, Actinic / drug therapy. Triterpenes / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18808378.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organic Chemicals; 0 / Triterpenes; 0 / oleogels; 6W70HN7X7O / betulin
  •  go-up   go-down


98. Szeimies RM, Matheson RT, Davis SA, Bhatia AC, Frambach Y, Klövekorn W, Fesq H, Berking C, Reifenberger J, Thaçi D: Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg; 2009 Apr;35(4):586-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study.
  • BACKGROUND: Photodynamic therapy (PDT) is an effective treatment for actinic keratoses (AKs).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Keratosis, Actinic / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309347.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


99. Smith SR, Morhenn VB, Piacquadio DJ: Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol; 2006 Feb;5(2):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp.
  • Actinic keratoses (AKs) are a common precancerous condition and are said to account for 14% of visits to dermatologists in the US each year.
  • Additionally, topical therapies have a perceived benefit of treating subclinical lesions along with clinically evident keratoses.
  • We conducted a bilateral comparison study of the efficacy and tolerability of diclofenac 3% gel used for 90 days and 5% fluorouracil cream used for 28 days in thirty patients with AK of the face and scalp.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Diclofenac / therapeutic use. Facial Dermatoses / drug therapy. Fluorouracil / therapeutic use. Keratosis / drug therapy. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485883.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antimetabolites, Antineoplastic; 0 / Gels; 144O8QL0L1 / Diclofenac; U3P01618RT / Fluorouracil
  •  go-up   go-down


100. Reuter J, Wölfle U, Korting HC, Schempp C: Which plant for which skin disease? Part 2: Dermatophytes, chronic venous insufficiency, photoprotection, actinic keratoses, vitiligo, hair loss, cosmetic indications. J Dtsch Dermatol Ges; 2010 Nov;8(11):866-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which plant for which skin disease? Part 2: Dermatophytes, chronic venous insufficiency, photoprotection, actinic keratoses, vitiligo, hair loss, cosmetic indications.
  • Extracts from the garden spurge (Euphorbia peplus) and from birch bark (Betula alba) have been shown to be effective in the treatment of actinic keratoses in phase II studies.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Dermatomycoses / drug therapy. Hypotrichosis / prevention & control. Keratosis, Actinic / drug therapy. Plant Extracts / therapeutic use. Venous Insufficiency / drug therapy. Vitiligo / drug therapy
  • [MeSH-minor] Chronic Disease / prevention & control. Cosmetics / classification. Cosmetics / therapeutic use. Humans. Sunscreening Agents / therapeutic use

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Hair Loss.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.
  • (PMID = 20707877.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Dermatologic Agents; 0 / Plant Extracts; 0 / Sunscreening Agents
  •  go-up   go-down






Advertisement